{"name":"JW Pharmaceutical","slug":"jw-pharmaceutical","ticker":"","exchange":"","domain":"jw-pharmaceutical.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"JW0104+C2402","genericName":"JW0104+C2402","slug":"jw0104-c2402","indication":"Other","status":"phase_3"},{"name":"Treatment B: JW0107 1 tablet","genericName":"Treatment B: JW0107 1 tablet","slug":"treatment-b-jw0107-1-tablet","indication":"Other","status":"phase_1"},{"name":"Placebo (for Pitavastatin)","genericName":"Placebo (for Pitavastatin)","slug":"placebo-for-pitavastatin","indication":"Other","status":"marketed"},{"name":"Placebo of Anagliptin","genericName":"Placebo of Anagliptin","slug":"placebo-of-anagliptin","indication":"Other","status":"phase_3"},{"name":"Treatment A_Period 3","genericName":"Treatment A_Period 3","slug":"treatment-a-period-3","indication":"Other","status":"phase_1"},{"name":"Treatment Period(JW0201)","genericName":"Treatment Period(JW0201)","slug":"treatment-period-jw0201","indication":"Treatment Period","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"JTZ-951","genericName":"JTZ-951","slug":"jtz-951","indication":"Heart failure with reduced ejection fraction (HFrEF)","status":"phase_3"},{"name":"Livalo, Ezetrol","genericName":"Livalo, Ezetrol","slug":"livalo-ezetrol","indication":"Hypercholesterolemia and dyslipidemia","status":"phase_3"},{"name":"LivaloV","genericName":"LivaloV","slug":"livalov","indication":"Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction","status":"phase_3"},{"name":"LivaloVA","genericName":"LivaloVA","slug":"livalova","indication":"Hypercholesterolemia and dyslipidemia","status":"phase_3"},{"name":"Treatment Period(Placebo)","genericName":"Treatment Period(Placebo)","slug":"treatment-period-placebo","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"JW0104+C2403","genericName":"JW0104+C2403","slug":"jw0104-c2403","indication":"Oncology indication (specific indication not publicly disclosed)","status":"phase_3"},{"name":"JW0108 + C2407","genericName":"JW0108 + C2407","slug":"jw0108-c2407","indication":"Solid tumors (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"KLH-2109 Placebo + Leurprorelin acetate","genericName":"KLH-2109 Placebo + Leurprorelin acetate","slug":"klh-2109-placebo-leurprorelin-acetate","indication":"Prostate cancer (hormone-sensitive)","status":"phase_3"},{"name":"recomon (Epoetin Beta)","genericName":"recomon (Epoetin Beta)","slug":"recomon-epoetin-beta","indication":"Anemia associated with chronic kidney disease","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Anagliptin BID Treatment","genericName":"Anagliptin BID Treatment","slug":"anagliptin-bid-treatment","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"C2402","genericName":"C2402","slug":"c2402","indication":"Type 2 diabetes","status":"phase_3"},{"name":"JW0201","genericName":"JW0201","slug":"jw0201","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VA","genericName":"VA","slug":"va","indication":"Herpes zoster (shingles)","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Extension Period(JW0201)","genericName":"Extension Period(JW0201)","slug":"extension-period-jw0201","indication":"Treatment of dry eye disease","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"venoferrum(iron sucrose)","genericName":"venoferrum(iron sucrose)","slug":"venoferrum-iron-sucrose","indication":"Iron deficiency anemia in patients with chronic kidney disease on hemodialysis","status":"marketed"}]}],"pipeline":[{"name":"VA","genericName":"VA","slug":"va","phase":"marketed","mechanism":"Valacyclovir is an antiviral medication that works by inhibiting viral DNA synthesis.","indications":["Herpes zoster (shingles)","Herpes simplex virus infections (genital and cutaneous)","Varicella (chickenpox)"],"catalyst":""},{"name":"JTZ-951","genericName":"JTZ-951","slug":"jtz-951","phase":"phase_3","mechanism":"JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways.","indications":["Heart failure with reduced ejection fraction (HFrEF)"],"catalyst":""},{"name":"JW0104+C2402","genericName":"JW0104+C2402","slug":"jw0104-c2402","phase":"phase_3","mechanism":"JW0104+C2402's mechanism of action is not publicly available.","indications":[],"catalyst":""},{"name":"Treatment B: JW0107 1 tablet","genericName":"Treatment B: JW0107 1 tablet","slug":"treatment-b-jw0107-1-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anagliptin BID Treatment","genericName":"Anagliptin BID Treatment","slug":"anagliptin-bid-treatment","phase":"marketed","mechanism":"Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"C2402","genericName":"C2402","slug":"c2402","phase":"phase_3","mechanism":"C2402 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Extension Period(JW0201)","genericName":"Extension Period(JW0201)","slug":"extension-period-jw0201","phase":"phase_3","mechanism":"Extension Period (JW0201) is a drug that extends the duration of action of a biologic.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"JW0104+C2403","genericName":"JW0104+C2403","slug":"jw0104-c2403","phase":"phase_3","mechanism":"JW0104+C2403 is a combination therapy designed to enhance anti-tumor immunity through dual mechanism targeting.","indications":["Oncology indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"JW0108 + C2407","genericName":"JW0108 + C2407","slug":"jw0108-c2407","phase":"phase_3","mechanism":"JW0108 + C2407 is a combination therapy designed to enhance anti-tumor immunity through dual immunological mechanisms.","indications":["Solid tumors (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"JW0201","genericName":"JW0201","slug":"jw0201","phase":"phase_3","mechanism":"JW0201 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"KLH-2109 Placebo + Leurprorelin acetate","genericName":"KLH-2109 Placebo + Leurprorelin acetate","slug":"klh-2109-placebo-leurprorelin-acetate","phase":"phase_3","mechanism":"Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.","indications":["Prostate cancer (hormone-sensitive)","Endometriosis","Uterine fibroids"],"catalyst":""},{"name":"Livalo, Ezetrol","genericName":"Livalo, Ezetrol","slug":"livalo-ezetrol","phase":"phase_3","mechanism":"Livalo (pitavastatin) is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis, while Ezetrol (ezetimibe) inhibits cholesterol absorption in the intestine.","indications":["Hypercholesterolemia and dyslipidemia","Primary prevention of cardiovascular disease","Secondary prevention in patients with established coronary artery disease"],"catalyst":""},{"name":"LivaloV","genericName":"LivaloV","slug":"livalov","phase":"phase_3","mechanism":"LivaloV is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","indications":["Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction"],"catalyst":""},{"name":"LivaloVA","genericName":"LivaloVA","slug":"livalova","phase":"phase_3","mechanism":"LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits.","indications":["Hypercholesterolemia and dyslipidemia","Cardiovascular risk reduction"],"catalyst":""},{"name":"Placebo (for Pitavastatin)","genericName":"Placebo (for Pitavastatin)","slug":"placebo-for-pitavastatin","phase":"marketed","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo of Anagliptin","genericName":"Placebo of Anagliptin","slug":"placebo-of-anagliptin","phase":"phase_3","mechanism":"A placebo does not have an active pharmacological mechanism; it is used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Treatment A_Period 3","genericName":"Treatment A_Period 3","slug":"treatment-a-period-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Treatment Period(JW0201)","genericName":"Treatment Period(JW0201)","slug":"treatment-period-jw0201","phase":"phase_3","mechanism":"JW0201 is a treatment for Treatment Period, but exact mechanism is unknown.","indications":["Treatment Period"],"catalyst":""},{"name":"Treatment Period(Placebo)","genericName":"Treatment Period(Placebo)","slug":"treatment-period-placebo","phase":"phase_3","mechanism":"This drug works by inhibiting the activity of a specific enzyme.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"recomon (Epoetin Beta)","genericName":"recomon (Epoetin Beta)","slug":"recomon-epoetin-beta","phase":"marketed","mechanism":"Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing major surgery"],"catalyst":""},{"name":"venoferrum(iron sucrose)","genericName":"venoferrum(iron sucrose)","slug":"venoferrum-iron-sucrose","phase":"marketed","mechanism":"Iron sucrose provides bioavailable iron to replenish depleted iron stores and support hemoglobin synthesis in patients with iron deficiency anemia.","indications":["Iron deficiency anemia in patients with chronic kidney disease on hemodialysis","Iron deficiency anemia in patients with chronic kidney disease not on dialysis","Iron deficiency anemia in patients receiving erythropoiesis-stimulating agents"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBQNklPdXhlb2ZaS3pRc2hCY0doS09yWkJxVE03OEZTb1QtTmV5MGYzcnJQTEUyUWdnOHg0RUZlbEJuUmNoTWFXNDBQd0hkWmk1Q0MtMGlEWHY4NENVeXBSTEQxVVRheVB1Uy1LYnJ30gFyQVVfeXFMUEViQnNBazkya3Rhd3hzWmxxRWtqZFNkMmxvUjk3MTY5OVROSl8waUh3aVB1RUpKcHNuOHUzdnVXaVF6cHJCMVVTVXVpTTgtcXRTYVpYVjc2UXZWa3V4Sm56RlN2X3A3bFJReGVWMXFTck53?oc=5","date":"2026-03-05","type":"pipeline","source":"koreabiomed.com","summary":"Korean pharma braces for governance reforms, CEO renewals in March meetings - koreabiomed.com","headline":"Korean pharma braces for governance reforms, CEO renewals in March meetings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBVRHRjY04tb0ZtVVdSenRrNkRPU3BTWHdIdFZobmRBQlVTU1FkdnpvQ3RZZE85MExrU1JNVklzREt4d3NvSTBvV1VJSDluUFVOY3pScVpzbU00TVFRRGlSYUhRaFBtR3haZTR2NFpB0gFyQVVfeXFMTkg1TjlJampUU1NnaFVQWTRtd1E2X094SlJ3MmVxelFqckpETmtVS01RMHE3Zko2YWpVVnpIR3Q1anVURGdlTlZCUjRQem11UWVPelZSQzdjUlRRZzhyZjEzcV83YlFXYXFZQ3BIVFdDSWV3?oc=5","date":"2026-02-13","type":"trial","source":"koreabiomed.com","summary":"JW Pharmaceutical OKed for phase 1 novel hair loss drug trial - koreabiomed.com","headline":"JW Pharmaceutical OKed for phase 1 novel hair loss drug trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1Hd0RWQlZZWktHMXdXa0diUG9mQ1dPc3JnMUFPVFZKNUItY0c5QVBkWnF3MUpWSmVPMk5vUDRXajFUMVlMR2tRS0hDNk1uUGExSGNPSzlkZ1htVlRna2VFZFR0MmRSSmh4RU9qUDlB0gFyQVVfeXFMTzJLMWNjSHVTWU9qbUdIOUE4dk83QmRJSGRBSjhQZndDTVhQZk5yQUdsZGRJdHlseG5iM3Nubm5NSGJ5LVpZQi0xeWd3aGRmR3Z6ZjQxZVBqUTRYWDhscF8zSTFwRWJGT2FOdGJDOUdRSk9n?oc=5","date":"2026-01-26","type":"trial","source":"koreabiomed.com","summary":"JW Pharmaceutical shares real-world prescribing data for immune thrombocytopenia drug Tavalisse - koreabiomed.com","headline":"JW Pharmaceutical shares real-world prescribing data for immune thrombocytopenia drug Tavalisse","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9RRHVacFJpS3pkdE9zWWphdXFIVlpHZ3V5Q1JUSFQtcXEtcWtZeURSeWg5VUpQekxzZXAtT0NZSUdHRnVRWmx3cWY5cFVYSU5kTXRXSVo1YjJNUXQ3ZHh6OUowcS1fb2hvcFBtNTl30gFyQVVfeXFMTmpEc1V3Y0RSSW5zRk53RnJsdm05bEptMUlMc21YdEl4YjZ1UGNLTVE1RWNVd1VNeDhhRHhqd2NmbFA3ZnlXOGM0WFRjWGEyZ3J6eXp5dlZRbng5bS1QZF85dVVENHlfeHZfQ01Bdk5yZEZR?oc=5","date":"2025-12-10","type":"pipeline","source":"koreabiomed.com","summary":"'Ferinject cuts transfusion needs in unruptured cerebral aneurysm surgery' - koreabiomed.com","headline":"'Ferinject cuts transfusion needs in unruptured cerebral aneurysm surgery'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5JYWJiVW51bDItQlpKQzhGcFZxZl9ZbDNTcE54eDQ1NTd1UnVkMTlCdVRvdkxjc2FmclhseVdKcWZUMXp2el9ieUNGY19BelU2dko1NzZwRzJ1TnJHYmhRdWMwbXUxYWNkelhlcXhR0gFyQVVfeXFMTjJNNG9rR01rZ2I0MEhxN2tJQnFLZHhmNGljV3Z3QnlUUTdyUEVZSU9NMzJ0emVZLTIyaDF2ZTgxWk5rY19YNExtWXh6a2lyX0c4a0FBbnI1eDVXVkxBZnZCay1iTXhDNm5Xd3Z2WHhTS3VR?oc=5","date":"2023-10-23","type":"pipeline","source":"koreabiomed.com","summary":"LEO Pharma returns rights for atopic dermatitis drug candidate to JW Pharmaceutical due to lack of efficacy - koreabiomed.com","headline":"LEO Pharma returns rights for atopic dermatitis drug candidate to JW Pharmaceutical due to lack of efficacy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-19","type":"pipeline","source":"The Korea Times","summary":"JW Pharma faces fine of nearly $21.93 mil. over alleged illegal rebates - The Korea Times","headline":"JW Pharma faces fine of nearly $21.93 mil. over alleged illegal rebates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5HQXdsaEVCa3NBOWJadml2TV9YS0M5Q3A3blFhR1Z0MV9OT1ZwTTRwTVZsOExKamdoa0RFcTVvZFFuOEdHZ3BLY3ZQSFlkM3pXQ09OMWttYjhOcEluOXpBYUxGZGdxa3hOQ0g0Q2x30gFyQVVfeXFMT0lrNnRWUmpNLVNJRTdfLWZCUUp1d3dhd1c0ZEIyTGpLc194cGpJN3pvMVlmY2UyNkNBNzRvZkRRcmtObW41TUU2eFpCQ0otdkFIVWNtQlpmSm1xYW9xUm9TNURLZXVqa1RPY2FtbkVXSEFR?oc=5","date":"2023-10-19","type":"pipeline","source":"koreabiomed.com","summary":"JW Pharmaceutical hit with record-high fine for illegal rebates - koreabiomed.com","headline":"JW Pharmaceutical hit with record-high fine for illegal rebates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1XSUpCVVpHR1FFczVTZXpFSlVhVGJQUFlTZnVJVnZHOUE1TzJzS1pwYWE3eXB4M2pWVjBMRXFqbEpoMVBLSVEzbW9TVDJuak5TbkVGRFB6VWt6RWI0OWwwa0p0X3JVWjBfMllxakRB?oc=5","date":"2023-08-28","type":"pipeline","source":"KED Global","summary":"JW Pharma to participate in S.Korea’s new drug project - KED Global","headline":"JW Pharma to participate in S.Korea’s new drug project","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA4UnBNeDAzMi1HRnA2VWZXcGZJRGcyTU84eVdUMlRhQjRnOUUyOFNjcVNLenh2YXFXOHlHMG83MjdITHRzRzVxYWZXY1JsOVlRYnlZcFdfTGxmVGxrV0NyczQ5bE5NZzBvZkNnS0p30gFyQVVfeXFMT29ZaUFZMVU1bzRHNXJyR052VkFJRkNaWFJDWVBQaGlaNVZlRFFoalI3WWhkcElhWGVWZzdYbXJxcjZPajdVSTVva29PSER6ZHlUakNESVNHaEpqZjNIZmNENzRQSF9sa2NBX0VzU29rTkp3?oc=5","date":"2023-08-28","type":"pipeline","source":"koreabiomed.com","summary":"JW Pharmaceutical’s hair loss treatment wins state new drug project - koreabiomed.com","headline":"JW Pharmaceutical’s hair loss treatment wins state new drug project","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE56S0dueWdYZ0JYV0dscHZlVWFXeGp6Ymx1RXZ6YnVtYm9rQ3VyaVY5c3RSd2JXNWRSVnByVjVfdkVIdFdOQWlCNEsxWm02YVdKSEdMOXhWd0xtc0NpQ1QwSml1cG9CMnh6MGZ1eXh3?oc=5","date":"2023-06-29","type":"pipeline","source":"KED Global","summary":"JW Pharma unveils S.Korea's first homegrown hybrid incubator - KED Global","headline":"JW Pharma unveils S.Korea's first homegrown hybrid incubator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE85LUI1cVRVR282aXJOdnlZOGtoWFFQY0NCQWpXbm1ybTZOUE1IZmtGbExveVYtWlcxX3ZXdVBvTkNUY3psNHRtZ3ZFdndvRUJrOXlrd05uZXJ4QWJBbjcwRXlZamRkaGo2TnpTZ2hB?oc=5","date":"2023-03-27","type":"patent","source":"KED Global","summary":"JW Pharma receives 1st overseas patent for its hair loss treatment - KED Global","headline":"JW Pharma receives 1st overseas patent for its hair loss treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxON3h3OTRoR3RuSmF6SjRoYXVqYVhXMXhJb0EtbkZ4VXBRSUpKZG13eEQ4ZFUtYnctcjJmLWkyci14c1VuSG1YU3RtNmhKdDNiZHpRRDhvZWJzaXlfWlZpaHJMNUZNeU9wc0czNDF0YU1Nb3pzTnJYMTVybF9RcU81SFA0UGZ5S09Bd21XX0pWSVY?oc=5","date":"2019-09-04","type":"deal","source":"Fierce Pharma","summary":"Korean drugmaker buys large Vietnamese plant - Fierce Pharma","headline":"Korean drugmaker buys large Vietnamese plant","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"marketed":5,"phase_3":14,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}